Everything in this lane is aiming at the same thing: a fuller natural growth-hormone pulse rather than injected growth hormone itself. The three options here get there by different routes, and one of them was once an approved medicine. Most comparisons skip that fact entirely. People searching this usually want to know whether the blend is worth it over a single compound — which turns out to be the wrong first question.
| CJC-1295 + Ipamorelin | Sermorelin | Ipamorelin | |
|---|---|---|---|
| Evidence tier | Preclinical onlyAnimal or mechanistic data plus community convention. No meaningful human evidence for the use discussed. | Human trialsSubstantial human clinical trial data exists, but the compound is not approved for the use discussed here. | Early human dataHuman data exists but is small, old, single-group, non-Western, or for a different route than people actually use. |
| Regulatory status | Not approved for human use | Formerly approved, discontinued | Not approved for human use |
| Researched for | A GHRH analogue plus a selective ghrelin-receptor agonist, studied together for a fuller natural GH pulse. | A GHRH analogue and one of the longest-standing tools in growth-hormone research. | A selective ghrelin-receptor agonist and GH secretagogue. Raises GH without meaningfully raising cortisol or prolactin. |
| What people use it for | Deeper, more restorative sleep (often the earliest reported effect); better workout recovery; gradual body-composition change. | Improved sleep quality; better recovery; increased energy; gradual lean-mass gains and body-fat reduction with consistent use. | A similar profile to the blend with simpler dosing and a smaller reconstitution volume: sleep, recovery, gradual composition change. |
| Reported figure | None given. | None given. | None given. |
| Route | Subcutaneous. No-DAC is dosed daily; DAC weekly — the single most consequential detail here. | Subcutaneous. The historical approval used a weight-based dose; today's flat adult figure is compounding-pharmacy convention. | Subcutaneous by convention. The human pharmacokinetic trials used weight-based IV infusions. |
| Calculator entry | Yes — CJC-1295 + Ipamorelin calculator | No calculator entry on this site. | Yes — Ipamorelin calculator |
Scroll the table sideways →
Sermorelin is the only one of the three that was ever an approved medicine, and almost nobody comparing them says so. This site’s grading notes it “was FDA-approved as Geref for paediatric growth hormone deficiency at a weight-based dose, withdrawn from the US market in 2009 — not for safety or efficacy reasons. Today's flat adult dose is compounding-pharmacy convention for an indication it was never approved for.” That is a genuine clinical pedigree attached to a different population, a different dosing basis, and a different purpose.
Ipamorelin sits at early human data. “Human pharmacokinetic trials were run in healthy volunteers using weight-based IV infusions, and showed it raises growth hormone without meaningfully raising cortisol or prolactin. For post-operative ileus it went further: a 114-patient phase 2 randomised trial exists (Beck 2014), and it missed its primary endpoint. The development programme ended before approval, and the flat microgram figure people inject is convention.” The selectivity finding is real; the injected schedule is not what was tested.
The blend is the least evidenced of the three, which is the inverse of how it is usually sold: “No human RCT has tested this combination. Each component has its own limited human pharmacology, but every outcome claim for the pair is community-reported.” Combining two compounds does not combine their evidence.
The detail that matters more than the matchup is buried in the same note: “the DAC vs no-DAC distinction matters enormously: no-DAC is dosed daily, DAC weekly.” Two products sold under the same name have completely different schedules. Getting that wrong is a larger practical error than any choice between these three.
Growth hormone
Education only. This page is educational. Most compounds referenced are not approved for human use, and a "research use only" label carries no legal status of its own.
A comparison, not a recommendation. Nothing on this page ranks one compound above another or suggests running either. Where a figure appears, it is one reported reference at the reconstitution shown — not a standard, not a clinical dose.
Reference ranges. Any amounts mentioned are values commonly reported in published research and community protocols, provided for reference only. Reported does not mean established, safe, or effective.
Not medical advice. Nothing here constitutes medical advice, diagnosis, or treatment. Several of these are prescription medicines in Canada and the US, and several are approved nowhere at all. Consult a qualified healthcare professional before beginning any protocol.